NEW YORK CITY, NY / ACCESS Newswire / November 5, 2026 / Cumberland Pharmaceuticals (NASDAQ: CPIX) shareholders lost almost 48.8% of their investment on October 26, 2026, after the Company reported that its Phase 2a ASSIST-SSc pilot study of ifetroban did not produce a clear efficacy signal. If you suffered a loss on your Cumberland Pharmaceuticals investment, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

Cumberland announced the top-line results of the trial on October 23, 2026. Levi & Korsinsky is investigating whether the Company issued false or misleading statements, or failed to disclose information material to investors, regarding the ifetroban program ahead of that announcement.

Investors who purchased Cumberland Pharmaceuticals shares and suffered losses can have their CPIX losses reviewed at no cost or reach Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

ABOUT THE FIRM -- For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the CPIX Investigation

Q: What is the CPIX securities fraud investigation about?
A: A securities investigation is pending concerning Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) regarding potentially materially false or misleading statements. Shares fell approximately 48.8% after the Company disclosed that its Phase 2a ASSIST-SSc study of ifetroban did not achieve a clear efficacy signal, causing losses for shareholders.

Q: Who is conducting the CPIX investigation?
A: Levi & Korsinsky, LLP is investigating potential securities fraud claims on behalf of investors who purchased CPIX securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered billions of dollars for aggrieved investors.

Q: Who is eligible to participate in the CPIX investigation?
A: Investors who purchased CPIX stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: What do CPIX investors need to do right now?
A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What is a lead plaintiff and why does it matter?
A: If the investigation proceeds to legal action, a lead plaintiff is the investor the court appoints to represent the group of affected investors. Lead plaintiffs are typically investors with the largest documented losses. Contacting the firm during the investigation phase preserves that option.

Q: What if I already sold my CPIX shares -- can I still recover losses?
A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought CPIX and sold at a loss may still participate in the investigation.

Q: What if my CPIX losses are small -- is it still worth contacting a lawyer?
A: Yes. There is no minimum loss amount required to participate in the investigation.

Q: What does it cost me to participate?
A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

SOURCE: Levi & Korsinsky, LLP